1. Home
  2. Clinical Evidence
  3. Basal-IQ Technology Satisfaction and Trust

Objective

To assess satisfaction and trust related to different insulin delivery devices (IDD) in people with type 1 diabetes (T1D) before and after starting Basal-IQ® technology on the t:slim X2™ insulin pump.

Method

Participants completed an online baseline survey including questions about their IDD (prior to Basal-IQ technology). This survey was repeated after 6 months (Post-Assessment) to assess participants’ experience with Basal-IQ technology. Participants elaborated on their experiences with their IDD in open-ended items on satisfaction and trust with their devices.

Results

Overall, there was a significant increase in both satisfaction and trust related to insulin delivery device after 6 months of Basal‑IQ technology use (p<0.001). Although a significant increase in IDD satisfaction was seen across participants (irrespective of Previous IDD type) at Post- Assessment, those on multiple daily injections (MDI) reported the largest increase in satisfaction (4.8 to 9.2, 91% increase), followed by previous Medtronic users (6.3 to 8.6, 36% increase). Previous MDI, OmniPod, and Medtronic users all showed a significant increase in IDD trust at Post-Assessment.

Conclusion

This study demonstrated notable improvements in IDD-related satisfaction and trust after 6 months of Basal-IQ technology use.

View Abstract Go to Publication

t:slim X2 Insulin Pump with Basal-IQ Technology

Product Documentation

Consult user guides for our pumps, infusion sets, predictive technology, and reporting app.

View Documentation

Product Training

Use our education tutorials to train your patients or CDEs on our easy-to-use products.

View Resources

Prescribing

Prescribing is easy with our customized referral process and insurance benefits check.

Learn More

Responsible Use of Basal-IQ Technology

Systems like the t:slim X2 insulin pump with Basal-IQ technology are not substitutes for the active management of diabetes. There are common scenarios in which automated systems cannot prevent a hypoglycemic event. The Basal-IQ feature relies on current CGM sensor readings to function and will not be able to predict glucose levels and suspend insulin delivery if a patient’s CGM is not functioning properly or his/her pump is unable to receive the CGM signal. It’s recommended your patient always uses the components of the pump system (pump, cartridges, CGM, and infusion sets) according to the applicable instructions for use and checks them regularly to make sure they are functioning as expected. Patients should always pay attention to their symptoms, actively monitor and manage glucose levels, and treat according to your recommendations.

References:
1. Forlenza GP, et al. Diabetes Care. 2018;41(10):2155-2161.
2. Editorial. Lancet Diabetes Endocrinol. 2019;7(9):657.
3. Subramanian S, et al. Diabetes Spectr. 2014;27(2):87-91.
4. Fleming GA, et al. Diabetes Care. 2020;43(1):250-260.
5. Tanenbaum ML, et al. J Diabetes Sci Technol. 2017;11(3):484-492.
6. Arafat Y, et al. The Use of Measurements ... Present Challenges and Future Solutions [Internet]. 2018
7. Liberman A, et al. Diabetes Technol Ther. 2016;18(Suppl 1):S101-S11.

Important Safety Information

Caution: Federal (USA) law restricts the t:slim X2 insulin pump and the t:slim X2 insulin pump with Basal-IQ technology to sale by or on the order of a physician. The t:slim X2 insulin pump with Basal-IQ technology (the System) consists of the t:slim X2 insulin pump, which contains Basal-IQ technology, and a compatible integrated continuous glucose monitor (iCGM, sold separately). The t:slim X2 insulin pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The t:slim X2 insulin pump can be used solely for continuous insulin delivery and as part of the System. When used with a compatible CGM, the t:slim X2 insulin pump with Basal-IQ technology can be used to suspend insulin delivery based on CGM sensor readings. The pump and the System are indicated for use in individuals 6 years of age and greater. The pump and the System are intended for single patient use. The pump and the System are indicated for use with NovoLog or Humalog U-100 insulin. The System is not indicated for use in pregnant women, people on dialysis, or critically ill patients. Users of the pump and the System must: be willing and able to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts. The t:slim X2 pump, transmitter, and sensor must be removed before MRI, CT, or diathermy treatment. For additional important safety information, visit www.tandemdiabetes.com/safetyinfo.